Profit180

Amneal Pharmaceuticals, Inc.

(AMRX)

Add Watchlist

6.82 USD -0.02

Closed: 17 May, 3:55 pm

Symbol	AMRX
Market Cap	2.1B
Price	6.82
Open	6.73
52-wk High	6.98
50 Day Avg	5.96
Earnings Announcement	2024-02-29
Website	https://www.amneal.com

Name	Amneal Pharmaceuticals, Inc.
Shares Outstanding	308,651,008
Change %	1.037%
Low	6.58
52-wk Low	2.15
200 Day Avg	5.00
Last Dividend	0.00

Exchange	NYSE
Volume	1,093,581
Previous Close	6.75
High	6.83
EPS	-0.73
PE	-9.34
Avg Volume	1,640,312
CUSIP	03168L105

Amneal Pharmaceuticals, Inc. Outlook

Description	Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
Currency	USD
ISIN	US03168L1052

Industry	Drug Manufacturers - Specialty & Generic
Changes	0.07
CUSIP	03168L105

Range	2.15 - 6.98
Beta	1.34
CIK	0001723128

03-May-2024 1:37 PM

Amneal Pharmaceuticals, Inc. (AMRX) Q1 2024 Earnings Call Transcript

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q1 2024 Results Earnings Conference Call May 3, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President and Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Executive Vice President and Chief Financial Officer Joe Renda - Senior Vice President, Chief Commercial Officer, Specialty Conference Call Participants Nathan Rich - Goldman Sachs Leszek Sulewski - Truist Securities David Amsellem - Piper Sandler Balaji Prasad - Barclays Capital Chris Schott - J.P. Morgan Operator Good morning and welcome to Amneal Pharmaceuticals First Quarter 2024 Earnings Call.

03-May-2024 11:00 AM

Drugmaker Amneal agrees to $270 million U.S. opioid settlement

Amneal Pharmaceuticals said on Friday it had reached a deal valued at more than $270 million to resolve claims it helped fuel the deadly U.S. opioid epidemic, becoming the latest drug company to settle lawsuits over the addiction crisis brought by states and local governments.